DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Above 50 Day Moving Average - Here's Why

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $8.89 and traded as high as $9.62. DBV Technologies shares last traded at $9.10, with a volume of 13,611 shares.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Citigroup reissued an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. HC Wainwright increased their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research report on Monday, May 5th. Wall Street Zen upgraded shares of DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday, May 9th. The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 target price for the company in a research note on Thursday, May 29th. Finally, JMP Securities increased their target price on shares of DBV Technologies from $15.00 to $21.00 and gave the stock a "market outperform" rating in a report on Tuesday, May 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, DBV Technologies presently has a consensus rating of "Hold" and an average target price of $14.75.

DBV Technologies Stock Down 6.1%

The stock has a fifty day moving average of $8.89 and a 200-day moving average of $5.90. The firm has a market capitalization of $249.25 million, a P/E ratio of -2.02 and a beta of -0.63.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The business had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. Sell-side analysts predict that DBV Technologies S.A. will post -7.05 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.